الفهرس | Only 14 pages are availabe for public view |
Abstract In a search for new cytotoxic agents with improved anticancer profile, some new thienopyrimidine and thienotriazolopyrimidine derivatives were synthesized. All the synthesized compounds are tested for their in-vitro cytotoxicity against human breast cancer cell line (MCF-7) in which tyrosine kinases are highly expressed. All target compounds are then subjected for further evaluation against receptor tyrosine kinase enzymes; namely, epidermal growth factor receptor (EGFR), (ErbB-2) and vascular endothelial growth factor receptor-2 (VEGFR-2).Compounds in series I were designed to be nonnucleoside reverse transcriptase inhibitors (NNRTIs). Compounds Va-f were assayed for their inhibitory activity against HIV-1 (IIIB strain) and HIV-2 (ROD strain) using nevirapine as a reference inhibitor. They were found to be moderately active against reverse transcriptase |